Editorial Board About Us

Alan W Partin

All articles from this author are listed below.

Volume 8, Number 1 Literature Reviews

Prostate Cancer

Literature Review

Alan W Partin Danil V Makarov

Volume 9, Number 4 Literature Reviews

Prostate Cancer

Reviewing the Literature

Alan W Partin Danil V Makarov

Volume 9, Number 3 Meeting Reviews

Best of the 2007 AUA Annual Meeting

Meeting Review

Jacob Rajfer Alan W Partin Michael B Chancellor J Curtis Nickel Claus G Roehrborn Michael K Brawer Dean G Assimos Danil V Makarov Ellen Shapiro

Highlights from the 2007 Annual Meeting of the American Urological Association May 19-24, 2007 Anaheim, CA [Rev Urol. 2007;9(3):133-154]

Prostate cancer Obesity Benign prostatic hyperplasia Antibiotic prophylaxis Nocturia Lower urinary tract symptoms Botulinum toxin Prostate-specific antigen Biomarkers PCA3 Testosterone Urinary tract infections Urolithiasis Laser ablation Endourology Male voiding dysfunction LHRH antagonists Antimuscarinic agents Circumcision Repeat biopsy Human glandularkallikrein Expectant management CRISP-3 MSP Microvesseldensity Endoglin Survivin Telomeres Interleukin-8 PDE-5 inhibitors Acute urinaryretention 5Alpha-reductase inhibitors Doxazosin Finasteride Transurethral microwave thermotherapy TURP Perioperative blood loss Microbialbiofilms HIV Stem cell injection

Volume 9, Number 2 Review Articles

The Impact of Definitions of Failure on the Interpretation of Biochemical Recurrence Following Treatment of Clinically Localized Prostate Cancer

Diagnostic Update

Alan W Partin Matthew E Nielsen

Widespread early detection with prostate-specific antigen (PSA) has radically transformed the clinical management of prostate cancer. PSA has become valuable in the monitoring and risk stratification of recurrent disease following local therapy. In many ways, biochemical recurrence–free survival, or PSA outcome, has become a surrogate measure of treatment efficacy following primary local therapy. Given the inherent differences in PSA kinetics following these treatment approaches, the definition of biochemical success or failure is not uniform among therapies. An appreciation of the inherent strengths, limitations, and biases of the standard definitions of failure can provide a more meaningful context within which to interpret the reported outcomes of different treatment modalities. [Rev Urol. 2007;9(2):57-62]

Prostate-specific antigen Radiotherapy Hormonal therapy Prostate cancer recurrence Biochemical failure Brachytherapy

Volume 9, Number 2 Literature Reviews

Prostate Cancer

Reviewing the Literature

Danil V Makarov Alan W Partin

Volume 9, Number 1 Literature Reviews

Prostate Cancer

Reviewing the Literature

Danil V Makarov Alan W Partin

Volume 10, Number 4 Literature Reviews

Prostate Cancer: Single Nucleotide Polymorphisms and Prostate Cancer Susceptibility

News and Views from the Literature

Stacy Loeb Alan W Partin

[Rev Urol. 2008;10(4):304-305]

Volume 10, Number 2 Literature Reviews

Prostate Cancer

News and Views from the Literature

Danil V Makarov Alan W Partin

Volume 10, Number 1 Literature Reviews

Prostate Cancer

Reviewing the Literature

Danil V Makarov Alan W Partin